We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. DermTech’s GEP-2 assay test is a noninvasive way to ...

Sentinel lymph node (SLN) status alone is not sufficient as node negative patients still experience relapse and melanoma-related death. Validates Merlin CP-GEP's prognostic power: Identifying tumors ...

SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for dermatology, hematology, and infectious & inflammatory diseases, announced today ...

“GEP testing provides significant value for clinicians and patients, and that’s exactly what we saw in our study. This molecular test provides an objective data point that can help improve definitive ...

New data analysis clarifies misleading benchmarks released by a competitor; separate SkylineDx analysis demonstrates Merlin CP-GEP Test provides stronger metastatic-risk stratification and superior ...

Please provide your email address to receive an email when new articles are posted on . Dermatologists should consider ordering a 31-gene expression profile test to determine metastasis risk in ...

Merlin CP-GEP test delivers high clinical utility – Study prospectively confirms precise risk stratification, optimizing SLNB referral recommendations. High clinical impact in subgroups – Merlin Low ...

Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC) could save on health care costs by utilizing the 40-gene expression profile (40-GEP) to guide treatment decisions. Patients ...

Newly validated i31-GEP algorithm integrates DecisionDx-Melanoma continuous score with clinicopathologic factors designed to provide a more precise, personalized likelihood of sentinel lymph node ...

An expert explains how gene-expression profile testing can inform treatment decisions for patients with squamous cell carcinoma. Gene-expression profile (GEP) testing among patients with squamous cell ...

Across primary sites, histological subtypes, and mitotic count categories, clinicopathological factors and gene-expression profile results were consistent for discriminating SLN positivity rates.

The MarketWatch News Department was not involved in the creation of this content. -- Sentinel lymph node (SLN) status alone is not sufficient as node negative patients still experience relapse and ...